메뉴 건너뛰기




Volumn 27, Issue 15, 2009, Pages 2417-2418

Radiopharmaceutical and chemotherapy combinations in metastatic castrate-resistant prostate cancer: A new beginning?

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; DOCETAXEL; DOXORUBICIN; LEXIDRONAM SAMARIUM SM 153; RADIOPHARMACEUTICAL AGENT; STRONTIUM 89; THALIDOMIDE; ANTINEOPLASTIC AGENT;

EID: 66349094853     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.21.4460     Document Type: Editorial
Times cited : (8)

References (10)
  • 1
    • 66349100456 scopus 로고    scopus 로고
    • Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer
    • Morris MJ, Pandit-Taskar N, Carrasquillo J, et al: Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer. J Clin Oncol 27:2436-2442, 2009
    • (2009) J Clin Oncol , vol.27 , pp. 2436-2442
    • Morris, M.J.1    Pandit-Taskar, N.2    Carrasquillo, J.3
  • 2
    • 66349089867 scopus 로고    scopus 로고
    • Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castrationresistant prostate cancer
    • Fizazi K, Beuzeboc P, Lumbroso J, et al: Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castrationresistant prostate cancer. J Clin Oncol 27:2429-2435, 2009
    • (2009) J Clin Oncol , vol.27 , pp. 2429-2435
    • Fizazi, K.1    Beuzeboc, P.2    Lumbroso, J.3
  • 5
    • 0027252452 scopus 로고
    • Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer
    • Porter AT, McEwan AJ, Powe JE, et al: Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 25:805-813, 1993
    • (1993) Int J Radiat Oncol Biol Phys , vol.25 , pp. 805-813
    • Porter, A.T.1    McEwan, A.J.2    Powe, J.E.3
  • 7
    • 79951895712 scopus 로고    scopus 로고
    • Market forces cited in lymphoma drugs' disuse
    • July 14
    • Berenson A: market forces cited in lymphoma drugs' disuse. New York Times, July 14, 2007. http://www.nytimes.com/2007/07/14/health/14lymphoma. html
    • (2007) New York Times
    • Berenson, A.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.